Orgenesis Stock

Orgenesis P/E 2024

Orgenesis P/E

50.82

Ticker

ORGS

ISIN

US68619K2042

WKN

A2H7XQ

As of Nov 8, 2024, Orgenesis's P/E ratio was 50.82, a -951.26% change from the -5.97 P/E ratio recorded in the previous year.

The Orgenesis P/E history

Orgenesis Aktienanalyse

What does Orgenesis do?

Orgenesis Inc is a company specializing in the development of therapies for the treatment of diabetes and other diseases. The company was founded in 2008 to advance research on new therapy approaches for diabetes treatment. Its business model is based on the development of cell therapy technologies to treat patients with diabetes. The company focuses on developing therapies that use human cells to regulate the body's immune system and improve insulin production. Orgenesis Inc also offers consulting services to help other companies develop similar technologies. The company's goal is to provide technology and know-how to drive industrial progress and help people worldwide. Orgenesis Inc is divided into several areas, including biotherapeutics, where it researches and develops therapeutic cell therapies for diabetes and other chronic diseases. It also operates in the engineering services sector, assisting with the design, construction, and development of other therapies and medical devices. The company also distributes products for monitoring diabetes in patients, such as innovative devices that monitor blood glucose and other important parameters, triggering alarms when certain thresholds are exceeded. In summary, Orgenesis Inc is a leading company in the research and development of cell therapy technologies in the field of diabetes and autoimmune therapy. It engages in a wide range of activities, from consulting services to engineering tasks and marketing its own products. This "closed loop" approach of research, development, and marketing has made Orgenesis Inc an innovative company that plays a significant role in the global healthcare industry. Orgenesis ist eines der beliebtesten Unternehmen auf Eulerpool.com.

P/E Details

Deciphering Orgenesis's P/E Ratio

The Price to Earnings (P/E) Ratio of Orgenesis is a vital metric that investors and analysts use to determine the company’s market value relative to its earnings. It is calculated by dividing the current stock price by the earnings per share (EPS). A higher P/E ratio could suggest that investors are expecting higher future growth, while a lower ratio may indicate a potentially undervalued company or lower growth expectations.

Year-to-Year Comparison

Assessing Orgenesis's P/E ratio on a yearly basis provides insights into the valuation trends and investor sentiment. An increasing P/E ratio over the years signifies growing investor confidence and expectations for future earnings growth, while a decreasing ratio may reflect concerns over the company's profitability or growth prospects.

Impact on Investments

The P/E ratio of Orgenesis is a key consideration for investors aiming to balance risk and reward. A comprehensive analysis of this ratio, in conjunction with other financial indicators, aids investors in making informed decisions regarding buying, holding, or selling the company’s stocks.

Interpreting P/E Ratio Fluctuations

Fluctuations in Orgenesis’s P/E ratio can be attributed to various factors including changes in earnings, stock price movements, and shifts in investor expectations. Understanding the underlying reasons for these fluctuations is essential for predicting future stock performance and assessing the company's intrinsic value.

Frequently Asked Questions about Orgenesis stock

What is the price-to-earnings ratio of Orgenesis?

The price-earnings ratio of Orgenesis is currently 50.82.

How has the price-earnings ratio of Orgenesis changed compared to last year?

The price-to-earnings ratio of Orgenesis has increased by -951.26% fallen (meaning "decreased" or "dropped") compared to last year.

What consequences does a high price-earnings ratio have for investors?

A high price-to-earnings ratio indicates that the company's stock is relatively expensive and investors may potentially achieve a lower return.

What does a low price-earnings ratio mean?

A low price-earnings ratio means that the company's stock is relatively cheap and investors may potentially achieve a higher return.

Is the price-earnings ratio of Orgenesis high compared to other companies?

Yes, the price-to-earnings ratio of Orgenesis is high compared to other companies.

How does an increase in the price-earnings ratio of Orgenesis affect the company?

An increase in the price-earnings ratio of Orgenesis would lead to a higher market capitalization of the company, which in turn would lead to a higher valuation of the company.

How does a reduction in the price-to-earnings ratio of Orgenesis affect the company?

A decrease in the price-earnings ratio of Orgenesis would result in a lower market capitalization of the company, which in turn would lead to a lower valuation of the company.

What are some factors that influence the price-earnings ratio of Orgenesis?

Some factors that influence the price-earnings ratio of Orgenesis are the company's growth, financial position, industry development, and the overall economic situation.

How much dividend does Orgenesis pay?

Over the past 12 months, Orgenesis paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Orgenesis is expected to pay a dividend of 0 USD.

What is the dividend yield of Orgenesis?

The current dividend yield of Orgenesis is .

When does Orgenesis pay dividends?

Orgenesis pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Orgenesis?

Orgenesis paid dividends every year for the past 0 years.

What is the dividend of Orgenesis?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Orgenesis located?

Orgenesis is assigned to the 'Health' sector.

Wann musste ich die Aktien von Orgenesis kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Orgenesis from 11/8/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 11/8/2024.

When did Orgenesis pay the last dividend?

The last dividend was paid out on 11/8/2024.

What was the dividend of Orgenesis in the year 2023?

In the year 2023, Orgenesis distributed 0 USD as dividends.

In which currency does Orgenesis pay out the dividend?

The dividends of Orgenesis are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von Orgenesis

Our stock analysis for Orgenesis Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Orgenesis Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.